Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical and medical device company. The company develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. The company’s product portfolio comprises approximately 1,800 products. Segments The company has two segments, Developed Markets and Emerging Markets. Developed Markets segment This segment consists of the sale in the United States of America (U.S.) of pharmaceutical products, OTC products, and medical device products, as well as alliance and contract service revenues, in the areas of dermatology and podiatry, neurology, gastrointestinal disorders, eye health, oncology and urology, dentistry, aesthetics, and women's health; and pharmaceutical products, OTC products, and medical device products sold in Western Europe, Canada, Japan, Australia, and New Zealand. Pharmaceutical Products The company’s principal pharmaceutical products comprise: Xifaxan, acquired as part of the Salix (Salix Pharmaceuticals, Ltd.) acquisition, including tablets indicated for the treatment of irritable bowel syndrome with diarrhea in adults (launched in 2015) and for the reduction in risk of overt hepatic encephalopathy recurrence in adults; and tablets indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years of age and older. Wellbutrin XL is an extended-release formulation of bupropion indicated for the treatment of major depressive disorder in adults. An Acne franchise, which includes Solodyn, a prescription oral antibiotic approved to treat the red, pus-filled pimples of moderate to severe acne in patients 12 years of age and older, as well as Ziana, Clindagel, Acanya, Atralin, Retin-A franchise and Onexton Gel, a fixed combination 1.2% clindamycin phosphate and 3.75% benzoyl peroxide medication for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 years of age and older. Glumetza (metformin hydrochloride) extended release tablets, acquired as part of the Salix acquisition, are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Provenge (sipuleucel-T), acquired as part of the acquisition of certain assets of Dendreon Corporation, is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. Jublia (efinaconazole 10% topical solution) is a topical azole approved for the treatment of onychomycosis of the toenails (toenail fungus). Nitropress (sodium nitroprusside), acquired as part of the acquisition of certain assets of Marathon Pharmaceuticals, LLC (Marathon), is indicated for the immediate reduction of blood pressure of patients in hypertensive crises. Isuprel (Isoproterenol hydrochloride) injections, acquired as part of the acquisition of certain assets of Marathon, is indicated for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy; for serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation); for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available; and for bronchospasm occurring during anesthesia. Xenazine is indicated for the treatment of chorea associated with Huntington’s disease. In the U.S., Xenazine is distributed for the company by Lundbeck LLC under a marketing, distribution and supply agreement. Uceris (budesonide) extended release tablets, acquired as part of the Salix acquisition, are a prescription corticosteroid medicine used to help get mild to moderate ulcerative colitis under control (induce remission). Lotemax Gel is a topical corticosteroid indicated for the treatment of post-
valeant pharmaceuticals inte
(VRX:New York Consolidated)
2150 St. Elzéar boulevard West
Laval, QC H7L 4A8
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for VRX.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact VALEANT PHARMACEUTICALS INTE, please visit www.valeant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.